Men with coronary artery disease who used phosphodiesterase-5 (PDE-5) inhibitors for erectile dysfunction had fewer adverse cardiovascular events than those taking the prostaglandin drug alprostadil ...

Men with stable CAD who are being treated for erectile dysfunction (ED) have a lower risk of dying if their medication is a phosphodiesterase 5 (PDE5) inhibitor rather than alprostadil, observational ...

Please provide your email address to receive an email when new articles are posted on . In a comparison of two erectile dysfunction medications in men with stable CAD, phosphodiesterase type 5, or ...

Use of a phosphodiesterase type-5 (PDE5) inhibitor was associated with a lower risk for death and cardiovascular events than alprostadil for the treatment of erectile dysfunction in men with stable ...

SAN DIEGO, March 31, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), announced today that the Mexican Patent Office ("MPO") will grant an additional patent for ...

Although ED is common, you don’t have to live with it. Our urological specialists understand your hesitation and frustration. We offer a range of personalized treatments to help you achieve the sexual ...

Erectile dysfunction (ED) is more common than many men realize and is often linked to a mix of physical, emotional, and lifestyle factors. Urologist John Smith, MD, explains what causes ED, how ...

Erectile dysfunction or impotency affects 18 to 20 million men every year in the United States. However, there has been a great change in treatment since 1998 when the first successful oral form of ...